Gary Kaplan, MD
Pulmonary Disease · Willoughby Hills, OHNPI 1023102324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by GSK at 27.5% of the total. Reporting peaked in 2023 at $936 and has fallen 95.8% since, to $39 in 2025.
Across 202 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$379
- Regeneron Healthcare Solutions, Inc.$329
- Boehringer Ingelheim$312
- Inspire Medical Systems, Inc.$252
- Sanofi$211
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 74 | $1,057 |
| AstraZeneca(2 entities) | 26 | $379 |
| Regeneron Healthcare Solutions, Inc. | 12 | $329 |
| Boehringer Ingelheim | 16 | $312 |
| Inspire Medical Systems, Inc. | 3 | $252 |
| Sanofi | 10 | $211 |
| Vapotherm Inc | 3 | $149 |
| Mallinckrodt Hospital Products Inc. | 7 | $142 |
| United Therapeutics Corporation | 1 | $120 |
| Novartis | 7 | $107 |
| Mylan Specialty L.p. | 5 | $104 |
| Amgen | 5 | $96 |
| Sunovion Pharmaceuticals Inc. | 6 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Genentech USA, Inc. | 5 | $73 |
| Merck | 3 | $69 |
| Grifols USA, LLC | 4 | $68 |
| Electromed, Inc. | 1 | $38 |
| Philips North America LLC | 2 | $26 |
| Harmony Biosciences LLC | 1 | $25 |
| Advanced Respiratory, Inc | 1 | $21 |
| Pulmonx Corporation | 1 | $19 |
| Inogen, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,842 in reported general payments places this provider in the 60th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 370 | $317,644 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $88,812 |
| Spiriva RespimatTiotropium Bromide | 79 | $58,355 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $54,043 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $38,798 |
| Spiriva HandihalerTiotropium Bromide | 33 | $33,527 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $33,289 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $27,374 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 91 | $13,941 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,397 |
| DuleraMometasone/Formoterol | 23 | $9,196 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 243 | $7,417 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $7,149 |
| Arnuity ElliptaFluticasone Furoate | 11 | $6,423 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,057 | $465,074626 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $312 | $112,398167 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $379 | $60,663115 claims |
| MerckDulera | $69 | $9,19623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Willoughby Hills
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
- Jean ElwingCincinnati$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.